Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates by Andrew E. Nixon et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 23 April 2015
doi: 10.3389/fimmu.2015.00176
Fully human monoclonal antibody inhibitors of the
neonatal Fc receptor reduce circulating IgG in
non-human primates
Andrew E. Nixon1, Jie Chen1, Daniel J. Sexton1, Arumugam Muruganandam1†, Alan J. Bitonti 2‡,
Jennifer Dumont 3, MaliniViswanathan1, Diana Martik 1†, DinaWassaf 1†, Adam Mezo2‡, Clive R.Wood 1†,
Joseph C. Biedenkapp1 and ChrisTenHoor 1*
1 Dyax Corp., Burlington, MA, USA
2 Syntonix Pharmaceuticals (a wholly-owned subsidiary of Biogen Idec.), Waltham, MA, USA
3 Biogen Inc., Cambridge, MA, USA
Edited by:
Jan Terje Andersen, Oslo University
Hospital, Norway
Reviewed by:
Peter Timmerman, Pepscan
Therapeutics B.V., Netherlands
Sampa Santra, Harvard Medical
School, USA
*Correspondence:
Chris TenHoor , Dyax Corp., 55
Network Drive, Burlington, MA
01803, USA
e-mail: ctenhoor@dyax.com
†Formerly affiliated with Dyax Corp.
‡Formerly affiliated with Biogen Inc.
The therapeutic management of antibody-mediated autoimmune disease typically involves
immunosuppressant and immunomodulatory strategies. However, perturbing the funda-
mental role of the neonatal Fc receptor (FcRn) in salvaging IgG from lysosomal degradation
provides a novel approach – depleting the body of pathogenic immunoglobulin by preventing
IgG binding to FcRn and thereby increasing the rate of IgG catabolism. Herein, we describe
the discovery and preclinical evaluation of fully human monoclonal IgG antibody inhibitors of
FcRn. Using phage display, we identified several potent inhibitors of human-FcRn in which
binding to FcRn is pH-independent, with over 1000-fold higher affinity for human-FcRn
than human IgG-Fc at pH 7.4. FcRn antagonism in vivo using a human-FcRn knock-in trans-
genic mouse model caused enhanced catabolism of exogenously administered human
IgG. In non-human primates, we observed reductions in endogenous circulating IgG of
>60% with no changes in albumin, IgM, or IgA. FcRn antagonism did not disrupt the abil-
ity of non-human primates to mount IgM/IgG primary and secondary immune responses.
Interestingly, the therapeutic anti-FcRn antibodies had a short serum half-life but caused
a prolonged reduction in IgG levels. This may be explained by the high affinity of the anti-
bodies to FcRn at both acidic and neutral pH. These results provide important preclinical
proof of concept data in support of FcRn antagonism as a novel approach to the treatment
of antibody-mediated autoimmune diseases.
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INTRODUCTION
Autoimmune diseases arise from abnormal immune responses
against substances and tissues normally present in the body.
More than 150 disorders have been classified as autoimmune or
autoimmune-related, affecting 5–8% of the general population
(1). In some disorders, IgG autoantibodies are the pathogenic
agents of disease and exert their effect through a variety of mecha-
nisms. These include neutralizing the activity of endogenous mol-
ecules, fixing of complement and activation of signaling cascades
to trigger cell lysis and phagocytosis, and formation of immune
complexes which instigate inflammation and interfere with organ
function. In addition, antibody responses to biologic replacement
therapies such as those used in the treatment of hemophilia and
lysosomal storage diseases result in clinical complications and
interfere with treatment (2–4).
Traditionally, there have been two main treatment strategies
for antibody-mediated autoimmune diseases: immunomodula-
tory and immunosuppressive therapies. Corticosteroids and small
molecule immunosuppressant agents have historically been first-
line therapies but in recent years, biologics including B-cell
depletion drugs such as rituximab and ofatumumab (5), plasma
cell depletion drugs such as bortezomib (6), and complement
inhibitors such as eculizumab (7, 8), have been used to treat a
variety of autoimmune diseases. While providing clinical benefit,
many of these drugs are associated with severe side-effects such
as infection that may be life-threatening (9–12). Immunomodula-
tory therapies include plasmapheresis, intravenous IgG (IVIG),
and immunoabsorption (13–19). These therapies are typically
used to control disease activity in the acute phase of the disease
through dilution or removal or reduction of serum autoantibod-
ies. However, these treatment approaches are expensive, require
complicated procedures, and carry risk of severe complications
(20). Thus, there remains an unmet need for therapeutic strategies
with an improved risk/benefit ratio.
Antagonism of the neonatal Fc receptor (FcRn) may repre-
sent an alternative approach to the treatment of diseases caused
by high levels of pathogenic IgG antibodies (1, 21, 22). FcRn,
initially identified as the neonatal receptor responsible for transcy-
tosis of IgG from mother to offspring to confer short-term passive
immunity, plays a critical role in IgG and albumin homeostasis
throughout adult life (23–26). In addition to its expression in
neonatal intestinal epithelial cells, it is expressed in a variety of
cell types, including the vascular endothelium and hematopoietic
cells (27–30). It is a heterodimeric receptor possessing an MHC
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class I-like heavy chain and a non-covalently associated light chain
β2-microglobulin (β2M) (31). Crystallography and site-directed
mutagenesis reveal that FcRn can bind both IgG and albumin on
opposite faces of the heavy chain (32–34). Significantly, the FcRn–
IgG/albumin interaction is highly pH-dependent, with higher
affinity at acidic pH than at neutral pH. This pH-dependent
binding is central to the role of FcRn in regulating systemic IgG
concentration.
IgG elimination primarily occurs through intracellular catab-
olism, following fluid-phase (pinocytosis) or receptor-mediated
endocytosis (35). When internalized, IgG can bind to FcRn in the
acidic environment of the endosome, thereby protecting it from
lysosomal degradation. The FcRn–IgG complex is then recycled
back to the cell surface where IgG dissociates at physiological pH.
In contrast, IgGs and other serum proteins which fail to bind
FcRn enter the lysosomal pathway and are degraded. Thus, the
pH-dependent binding of FcRn to IgG (and albumin) is the cen-
tral mechanism underlying the extended serum half-life of these
two plasma proteins. The potential to modify the serum half-
life of engineered proteins through their interaction with FcRn
was quickly recognized and has since been capitalized upon to
maximize the pharmacokinetics and bioavailability of therapeutic
antibodies and related biologics (36–38).
Previous studies have demonstrated that mice lacking FcRn
have accelerated IgG catabolism and are less susceptible to induc-
tion of various autoimmune diseases (39–41). It has also been
suggested that the therapeutic benefit of IVIG in the treatment
of various autoimmune diseases, may result in part from FcRn
saturation and enhanced catabolism of endogenous IgG (40, 42)
though not in a mouse model of immune thrombocytopenia (43).
IgG and peptide antagonists of FcRn have also been developed and
administration of these molecules to mice (44–47), rats (48), and
non-human primates (45) accelerated IgG catabolism and reduced
disease severity in animal models of myasthenia gravis, arthritis,
and glomerular disease (46, 48, 49). Taken together, blockade of
IgG binding to FcRn increases the rate of IgG catabolism and has
the potential to deplete the body of pathogenic immunoglobulin,
representing a potentially novel treatment to reduce pathological
IgG autoantibodies.
Herein, we describe the discovery and characterization of fully
human monoclonal antibodies that bind with high affinity to
human-FcRn at both acidic (pH 6.4) and neutral (pH 7.0) (i.e.,
pH-independent binding). Following administration of anti-FcRn
antibody to rodents and non-human primates, significant reduc-
tions in circulating IgG with no changes in albumin, IgM, or
IgA were observed. In non-human primates, we observed no evi-
dence of immunosuppression, as monkeys maintain the ability
to mount IgM/IgG primary and secondary immune responses
in the presence of anti-FcRn antibody. Interestingly, the anti-
FcRn antibodies had a short serum half-life but caused a durable
and extended reduction in IgG levels, such that serum levels of
anti-FcRn antibody did not correlate directly with pharmacody-
namic activity. Preliminary studies in rodents and non-human
primates found the antibody to be well-tolerated. These results
suggest anti-FcRn antibodies may represent a novel therapeutic
approach to the treatment of IgG antibody-mediated autoimmune
diseases.
MATERIALS AND METHODS
PHAGE DISPLAY SELECTION
Soluble human-FcRn expression and purification
Soluble human-FcRn (shFcRn) was prepared as previously
described (45).
Antibody expression and purification
Fabs were expressed in E. coli and purified using protein A
sepharose as described previously (50). Recombinant Fab frag-
ments were reformatted into full-length human IgG1 antibodies
(F-allotype) and either produced by transient transfection in HEK
293T cells as described (51), or stably transfected into CHO
(Chinese-hamster ovary) cells using the glutamine synthetase
expression system (Lonza Biologics), expressed using a fed-batch
fermentation strategy, and purified as previously described (52).
Phage display selection
Human antibodies against FcRn were identified from an antibody
phage display library (53) using biotinylated shFcRn immobilized
on streptavidin-coated magnetic beads (Dynal, M280) and cells
expressing hFcRn.
(1) For selections against biotinylated shFcRn, biotinylated
shFcRn was initially immobilized on streptavidin beads. Prior
to the first selection round, the antibody library was depleted
on uncoated streptavidin beads by allowing the library phage
to incubate at room temperature for 10 min before removing
the supernatant containing the phage and proceeding into the
first round of selection.
Phage were allowed to bind to immobilized shFcRn in an acidic
binding buffer (pH 6), and were then eluted with polyclonal
human IgG (Calbiochem, Catalog # 401114) and monoclonal
mouse anti-human-FcRn mAb (3B3) in an acidic buffer. After this
competitive elution, all remaining bead-bound phage were used
to directly infect E. coli and the amplified phage output was used
as input for next round of selection. Three rounds of selection
against immobilized FcRn protein were performed.
(2) Three rounds of selection against hFcRn- transfected cells
were carried out with depletion on an untransfected parental
cell line. Phage were allowed to bind to cells in an acidic bind-
ing buffer (pH 6), and then were eluted with non-specific
human IgG and anti-FcRn mAb (3B3) in the same acidic
buffer. After this competitive elution, all remaining bead-
bound phage were used to directly infect E. coli and the
amplified phage output was used as input for next round of
selection.
Primary screening
Phage isolates were screened by ELISA (streptavidin-immobilized
shFcRn with detection by anti-M13 coat protein VIII), positive hits
were DNA-sequenced, and unique Fabs batch-processed for E. coli
expression as isolated Fab fragments from the pMID21 vector as
described (50).
Affinity maturation
An affinity maturation library was constructed from the lead
Fab by employing mixed nucleotide synthesis of heavy chain
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variable complementary determining region 3 (HV-CDR3) where
the nominal base was present at 85% and each of the others at
5%. The library repertoire of HV-CDR1 and CDR2 were added to
the parent heavy chain for a set of affinity matured variants. The
high-affinity variants from HV-CDR1–2 and HV-CDR3 affinity
maturation were combined to create a small population for screen-
ing of improved variants. A germlined light chain was used to build
the affinity maturation library in order to avoid further sequence
optimization.
Affinity maturation library selection
Library selections were carried out using a combination of cells
and protein targets with lower protein targets concentrations in
each round for selection of high-affinity variants.
(1) Selections against biotinylated shFcRn: two rounds of selec-
tion against biotinylated shFcRn were carried out with deple-
tion on uncoated streptavidin beads as described previously.
Phage were allowed to bind to target in acidic binding buffer
(pH 6), and were then eluted with parental M90-F11 IgG in a
pH 7.4 buffer (parental M90-F11 IgG was the lead anti-FcRn
antibody identified during the primary screening campaign).
After competitive elution/wash, all remaining bead-bound
phage were used to directly infect E. coli. The eluted phage
output was used as input for the next round of selection.
Round 2 output was used in alternate round 3 selection against
hFcRn-transfected cells followed by a fourth round selection
using biotinylated shFcRn selections using the same elution
strategy.
(2) Selections against hFcRn expressing cells: two rounds of selec-
tion against hFcRn-transfected cells were carried out. Phage
were allowed to bind to cells in acidic binding buffer (pH 6)
at 4°C, and were then eluted with parental M90-F11 IgG in
a pH 7.4 buffer. After competitive elution/wash, all remain-
ing bead-bound phage were eluted by cell lysis with magnetic
streptavidin beads and subsequent infection of bacteria. The
eluted phage output was used as input for next round of selec-
tion. Two additional rounds of selection against biotinylated
shFcRn were carried out as described in (1).
SURFACE PLASMON RESONANCE ANALYSIS OF ANTI-FcRn VARIANTS
Surface plasmon resonance (SPR) measurements were performed
using a BIAcore 3000 (GE Healthcare). Anti-FcRn variants were
immobilized by amine coupling on CM5 sensor chips. To mea-
sure the kinetic parameters of anti-FcRn antibody interactions
with FcRn analyte, twofold serial dilutions prepared from 100 nM
of FcRn were injected in duplicate for 5 min at 50µl/min with a
15-min dissociation phase. The sensor chip surface was regen-
erated with a 30-s pulse of 10 mM glycine pH 1.5 at a flow
rate of 75µl/min followed by a 15-s pulse of buffer. Measure-
ments were performed at 25°C using HBS-P (10 mM HEPES,
150 mM NaCl, and 0.005% surfactant P20 at pH 6.0 and pH
7.5) as the running buffer. The reference flow cell was acti-
vated and blocked in a mock amine coupling reaction. The
data were fit to a 1:1 binding model using BIAevaluation v.4.1
software.
EXPERIMENT 1: IgG CATABOLISM AND PHARMACOKINETICS OF THE
ANTI-FcRn ANTIBODY DX-2504 IN hFcRn TRANSGENIC MICE (TG32B)
TG32B mice
Transgenic mice expressing hFcRn [“TG32B,” mFcRn (−/−),
mβ2M (−/−), hFcRn (+/+), hβ2M (+/+)] were originally
obtained from Dr. Derry Roopenian (The Jackson Laboratory).
All animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) and performed in accordance with
the Guide to the Care and Use of Laboratory Animals.
IgG catabolism in transgenic mice
TG32B mice (n= 4) received 500 mg/kg hIgG intravenously.
Twenty-four hours later, approximately 60µl of blood was col-
lected by a tail snip prior to dosing the mice with intravenous
(IV) or SC DX-2504 (12.21 mg/ml). Additional blood samples
were collected from each mouse at 0.5, 24, 48, 72, 96, and 144 h
after administration of DX-2504. Serum was prepared and stored
at−20° C.
hIgG ELISA
Serum levels of human IgG were measured using a specific hIgG
ELISA. Briefly, 96 well plates were coated with 50µl/well goat
anti-human IgG (Fab-specific) antibody (Pierce Biotechnology,
Rockford, IL, USA, Catalog # 31122) at 4°C overnight. Plates were
then blocked with 200µl/well of 2% bovine serum albumin (BSA)
in phosphate buffered saline (PBS) for 1 h at 37°C. Samples and
standards (100µl/well) were diluted in 2% BSA/PBS and incu-
bated at 37°C for 1 h. The standard curve of hIgG ranged from 200
to 1.56 ng/ml in twofold dilutions. Plates were then washed three
times with 300µl/well PBS supplemented with 0.05% Tween-20
(PBST) in a Tecan plate washer before adding 100µl/well goat
anti-human IgG (Fc-specific)-horseradish peroxidase (HRP) con-
jugate (Pierce Biotechnology, Catalog # 31413) diluted 1:25,000
in 2% BSA/PBS. Plates were incubated with detection antibody
for 1 h at 37°C before again washing three times with PBST.
Reactions were developed with 100µl/well TMB substrate (Super-
sensitive 1-component HRP substrate, BioFX, Owing Mills, MD,
USA, Catalog # TMBS-0100-01) at room temperature for approx-
imately 4 min. Reactions were stopped by addition of 100µl/well
0.25 M sulfuric acid, and plates were read at 450 nm using a
Spectramax spectrophotometer (Molecular Devices, Sunnyvale,
CA, USA). The standard curve was then used to calculate serum
concentration of IgG.
Measurement of anti-FcRn antibody DX-2504 in mouse serum
Serum concentration of DX-2504 was measured using a specific
hIgG ELISA. Briefly, 96 well plates were coated with 50µl/well goat
anti-human IgG (Fab-specific) antibody (Pierce Biotechnology,
Rockford, IL, USA, Catalog # 31122) at 4°C overnight. Plates were
then blocked with 200µl/well of 2% BSA in PBS for 1 h at 37°C.
Samples and standards (100µl/well) were diluted in 2% BSA/PBS
and incubated at 37°C for 1 h. The standard curve ranged from
200 to 1.56 ng/ml of DX-2504 in twofold serial dilutions. In addi-
tion, a known amount of DX-2504 was spiked into 100% trans-
genic mouse serum, which was then diluted to correspond to the
dilution factor used for unknown samples (e.g., 1:5,000, 1:2,000,
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etc.). The concentration of spiked DX-2504 in the 100% mouse
serum sample varied depending on the final dilution factor of the
unknowns, with the objective to choose a spiked concentration
that was expected to fall on the linear portion of the standard curve.
Plates were then washed three times with 300µl/well of PBS sup-
plemented with 0.05% Tween-20 (PBST) in a Tecan plate washer
before adding 100µl/well goat anti-human IgG (Fc-specific)-HRP
conjugate (Pierce Biotechnology, Rockford, IL, USA, Catalog #
31413) diluted 1:25,000 in 2% BSA/PBS. Plates were incubated
with detection antibody or 1 h at 37°C before again washing three
times with PBST. Reactions were developed with 100µl/well TMB
substrate (Supersensitive 1-component HRP substrate, BioFX,
Owing Mills, MD, USA, Catalog # TMBS-0100-01) at room tem-
perature for approximately 4 min. Reactions were stopped by
addition of 100µl/well 0.25 M sulfuric acid, and absorbance was
measured at 450 nm using a Spectramax spectrophotometer (Mol-
ecular Devices, Sunnyvale, CA, USA). The standard curve was used
to calculate serum concentrations of DX-2504.
EXPERIMENT 2: IgG CATABOLISM AND PHARMACOKINETICS OF
ANTI-FcRn ANTIBODY DX-2504 IN CYNOMOLGUS MONKEYS
The study included 15 female cynomolgus monkeys from the New
Iberia Research Center (NIRC) colony which were between 2.5 and
3.55 kg body weight. The study was conducted under an approved
NIRC IACUC protocol at NIRC in New Iberia, LA, USA and per-
formed in compliance with the protocol and UL Lafayette-NIRC
Standard Operating Procedures. There were three monkeys per
dose group, which included animals treated with IV vehicle (PBS,
pH 7.2) or with DX-2504 (11.6 mg/ml) in PBS (pH 7.2) at 5 mg/kg
(IV), 20 mg/kg (IV), 5 mg/kg (SC), or 20 mg/kg (SC). Each animal
received in a volume of 1.72 ml/kg (in a peripheral vein IV and
in the dorsal-scapular region SC) a dose on day 0 and on day 7
and blood samples were collected for serum approximately 30 min
before each dose and then at 0.25, 2, 8, 12, 24, 48, 72, 96, 120, 144,
and 168 h after each dose of DX-2504. IgG, IgA, IgM, and albumin
concentrations in serum were measured using nephelometry and
DX-2504 in serum was measured by ELISA.
Nephelometric measurement of immunoglobulin and albumin in
serum from cynomolgus monkeys
Serum IgG, IgA, IgM, and albumin were measured in monkey
serum using a BNII nephelometer (Siemens, Malvern, PA, USA).
Serum samples were loaded into the instrument, which diluted
each sample individually; IgG and albumin samples were diluted
a minimum of 1:400 and the IgA and IgM a minimum of 1:20.
For each test (IgG, IgA, IgM, or albumin), the diluted sample was
mixed with an antiserum specific to the particular test and the
amount of precipitation was measured by detecting the amount
of light scattering of the particles. The results, expressed in mil-
ligram per milliliter, are calculated from standard curves using
known calibrator reagents.
Measurement of anti-FcRn antibody DX-2504 in serum from
cynomolgus monkeys
DX-2504 in serum was measured using a species-specific IgG
ELISA. All unknown samples, quality controls (QCs), and stan-
dards were tested in duplicate wells. Briefly, 96 well plates (Costar,
Catalog # 3369) were coated with 100µl/well of goat anti-human
IgG (H+ L chain) monkey pre-absorbed (Bethyl Labs, Mont-
gomery, TX, USA, Catalog # A80-319A) at a concentration of
1µg/ml in 50 mM carbonate/bicarbonate pH 9.6 buffer solution
(Sigma, St. Louis, MO, USA, Catalog # C3041-100CAP) and incu-
bated at 37°C for 1 h (light plate shaking setting). After 1 h, plates
were washed manually three times with 200µl of 1×PBS sup-
plemented with 0.5% Tween-20 (0.5% PBST) before they were
blocked (200µl/well) with 3% BSA (Jackson ImmunoResearch,
West Grove, PA, USA, Catalog # 001-000-173) in PBS (Gibco,
Grand Island, NY, USA, Catalog # 10010-023) and incubated
for 1.5 h at 37°C (light plate shaking setting). Once plates were
blocked, blocking solution was removed and the plate was blotted
dry on paper towels. The standard curve was generated using DX-
2504 (stock conc. 11.6 mg/ml) prepared in 100% pooled plasma
from untreated monkeys, and then diluted serially twofold with
pooled monkey plasma, starting from 1000 to 7.81 ng/ml. Each
standard was then diluted 10-fold in 3% BSA/PBS to make a
final standard curve with concentrations ranging from 100 to
0.78 ng/ml. QC samples were also included on the plates and pre-
pared in the same manner as the standards. We included three QC
samples corresponding to the expected ranges on the standard
curve: high (80 ng/ml); middle (15 ng/ml), and low (4 ng/ml).
Unknowns, QC, and standards (100µl/well) were incubated at
37°C for 1 h (no plate shaking). Plates were then washed man-
ually four times (200µl/well) with 0.5% PBST before adding
100µl/well of goat anti-human IgG (H+ L chain)-HRP conju-
gated (Bethyl Labs, Montgomery, TX, USA, Catalog # A80-319P-8)
diluted 1:25,000 in 3% BSA/PBS. Plates were incubated with detec-
tion antibody for 1 h at 37°C before washing four times manually
with 0.5% PBST. Reactions were developed with 100µl/well TMB
substrate (Neogen Labs Enhanced K-blue, Catalog # 308177) at
room temperature in the dark (no plate shaking) for approxi-
mately 10 min. Reactions were stopped by addition of 100µl/well
of 0.25 M sulfuric acid. Absorbance at 450 nm was monitored
using a Spectramax spectrophotometer (Molecular Devices, Sun-
nyvale, CA, USA). The standard curve (four parameter logistical
curve fit) was then used to calculate the serum concentration of
DX-2504 vs. time.
EXPERIMENT 3: EFFECT OF ANTI-FcRn ANTIBODY DX-2504 ON
HUMORAL IMMUNE RESPONSE TO MODEL ANTIGENS KEYHOLE
LIMPET HEMOCYANIN AND TETANUS TOXOID IN CYNOMOLGUS
MONKEYS
The study included 18 naïve cynomolgus monkeys (9 males, 9
females) from the NIRC colony which were between 2.5 and
5.95 kg body weight. The study was conducted under an approved
NIRC IACUC protocol at NIRC in New Iberia, LA, USA and per-
formed in compliance with the protocol and UL Lafayette-NIRC
standard operating procedures.
There were three study groups with three male and three female
cynomolgus monkeys per group. Group 1 served as the con-
trol group (Vehicle, SC, dose volume of 1.75 ml/kg). On day 0,
Group 1 animals were immunized with tetanus toxoid (TT) in
the quadriceps muscle in 0.1 ml/kg. On day 28, Group 1 animals
were dosed with Vehicle followed by keyhole limpet hemocyanin
(KLH) in 0.5 ml (in the contralateral quadriceps muscle) and
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TT immunizations as above. Additionally, Group 1 was dosed
with Vehicle on days 35 and 42. Group 2 received the same
immunizations as Group 1, but was also administered DX-2504
(11.46 mg/ml) at 20 mg/kg SC on days 28 (prior to immunization
with KLH and TT), 35, and 42. Group 3 received the same immu-
nization treatment as Group 1, but DX-2504 was administered
at 20 mg/kg SC on days 31, 38, and 45. DX-2504 was adminis-
tered in the dorsal-scapular region in a volume of 1.75 ml/kg. A
recovery period was included after the last dose of DX-2504 (25–
28 days post-dose) to allow for blood sampling for serum in order
to monitor the recovery of serum IgG levels. Blood was collected
for serum (always prior to dosing) on days 0, 3, 7, 10, 14, 17,
21, 24, 28, 31, 35, 38, 42, 45, 49, 52, 59, and 70. Serum IgG, IgA,
IgM, and albumin were measured in monkey serum using a BNII
Nephelometer (Siemens, Malvern, PA, USA) as described. Ani-
mals received multiple vaccinations with TT prior to the start of
the study and therefore use of this antigen was to model a sec-
ondary immune response. KLH was a novel antigen and used to
model a primary immune response.
Keyhole limpet hemocyanin was (Imject® mcKLH, Pierce,
Rockford, IL, USA, Catalog # 77600) reconstituted with 1 ml of
Sigma Water (Double Processed, sterile filtered, Catalog # W3500)
to make a 20 mg/ml solution. TT vaccine (Super-Tet® with Havlo-
gen®; manufactured by Intervet/Schering-Plough Animal Health,
supplied by Butler Animal Health) was stored and prepared for
intramuscular injection as specified by the manufacturer.
Measurement of anti-KLH antibodies in serum from non-human
primates
Antibodies against KLH were quantified using kits that measure
either monkey anti-KLH IgM (Monkey Anti-KLH IgM ELISA Kit,
Life Diagnostics, Catalog # 4000-4) or monkey anti-KLH IgG
(Monkey Anti-KLH IgG ELISA Kit, Life Diagnostics, Catalog #
4010-4) as per the instructions of the manufacturer. For both
assay kits, the levels of monkey anti-KLH antibodies are reported
in nominal units derived from standard curves generated using
calibrated standards.
Measurement of anti-TT antibodies in serum from non-human
primates
Antibodies against TT were quantified using kits that measure
either monkey anti-TT IgM (Monkey Anti-TT IgM ELISA Kit,
Life Diagnostics, Catalog # 4300-4) or monkey anti-TT IgG (Mon-
key Anti-TT IgG ELISA Kit, Life Diagnostics, Catalog # 4310-4)
as per the instructions of the manufacturer. For both assay kits,
the levels of monkey anti-TT antibodies are reported in nomi-
nal units derived from standard curves generated using calibrated
standards.
EXPERIMENT 4: A PHARMACOLOGIC COMPARABILITY AND
TOXICOKINETIC STUDY OF ANTI-FcRn ANTIBODIES DX-2504 AND
DX-2507 IN CYNOMOLGUS MONKEYS
Six female cynomolgus monkeys weighing 3.2–3.4 kg originally
sourced from Primate Products, Inc. (Miami, FL, USA) were trans-
ferred to the WIL Research Laboratories, LLC (Ashland, OH, USA)
stock colony. Animals were maintained in accordance with the
“Guide for the Cafe and Use of Laboratory Animals” (National
Research Council, 1996). All monkeys were provided with an
enriched environment in accordance with the WIL Research SOPs,
and the Animal Welfare Act (9 CFR Part 3). The facilities at WIL
Research Laboratories, LLC are fully accredited by the Associa-
tion for Assessment and Accreditation of Laboratory Animal Care
International (AAALAC International).
DX-2504 (18.2 mg/ml) or DX-2507 (34.6 mg/ml) in citrate–
phosphate–trehalose buffer (100 mM citrate–phosphate buffer,
50 mM NaCl, 2% Trehalose, 0.01% Tween® 80, pH 6.0) was admin-
istered via single SC injections on study days 0 and 7 to two groups
(Groups 1 and 2) of female cynomolgus monkeys. Dose levels were
20 mg/kg DX-2504 and 20 mg/kg DX-2507. Each group consisted
of three females.
The animals were observed twice daily for mortality and mori-
bundity. Clinical examinations were performed daily and detailed
physical examinations were performed approximately weekly.
Individual body weights were recorded at least once during the
pretest period, prior to dosing on study days 0 and 7, and approx-
imately weekly during the recovery period. Blood samples for
toxicokinetics and immunoglobulin assessments were collected
from all animals prior to dosing and at approximately 2 and 12 h
post-dosing on study days 0 and 7. On study days 1, 2, 3, 4, 5, and
6, blood samples for toxicokinetics and immunoglobulin assess-
ments were collected from all animals based on the time of dose
administration on study day 0 (±2 h). On study days 8, 9, 10,
11,12, 13, 14, 17, 21, 24, 28, 31, and 35, blood samples for toxico-
kinetics and immunoglobulin assessments were collected from all
animals based on the time of dose administration on study day
7 (±2 h). Following the final blood collection for toxicokinetics
and immunoglobulin assessments, all animals were returned to
the colony (study day 35).
RESULTS
DISCOVERY OF ANTI-FcRn ANTIBODIES BY ANTIBODY PHAGE DISPLAY
AND AFFINITY MATURATION
One-hundred sixty one unique phagemids that passed the sec-
ondary ELISA screening had distinct heavy chains. All 161 unique
phagemids were subcloned and expressed as sFabs and screened
in a FACS blocking assay of IgG-Fc to FcRn on 293C11 cells.
This blocking assay yielded eleven sFabs with antagonistic anti-
FcRn properties. The 11 sFabs were sequenced and reformatted to
IgG1, AZ allotype, and further characterized for hFcRn binding by
SPR analyses, which identified M90-F11 as the candidate with the
highest affinity.
Parental clone M90-F11 was germlined and reformatted to
F-allotype and designated DX-2500. Biacore SPR analysis of DX-
2500 indicated unacceptable rapid koff rates at both pH 6.0 and
pH 7.4 [koff (/s)= 1.77× 10−2 and 7.52× 10−2, respectively]. To
improve the koff rate, the germlined M90-F11 parental was affinity
matured and a second selection campaign was conducted against
hFcRn. Twenty-four sFab clones were sequenced, purified, shown
to block IgG binding in FACS analysis, ranked in FcRn binding
affinity by SPR analysis, and reformatted to IgG. Four IgG clones
were selected for additional in vitro and in vivo testing. Based on
in vitro and in vivo test results, plus expression and purification
performance, clone M161-B04 was chosen as the lead antibody
and was designated DX-2504 for further in vivo development.
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DX-2504 has an unpaired cysteine residue in LC-CDR3 which
was conserved during germlining. A free cysteine can result in
disulfide bond shuffling, oxidation, and disulfide-linked aggrega-
tion impacting the antibody manufacturing process and product
stability (54, 55). To mitigate this risk, the free cysteine in the
LC-CDR3 in DX-2504 was mutated to an alanine. In addition, a
C-terminal lysine residue was removed to eliminate charge variants
derived from lysine cleavage to generate the variant of DX-2504
known as DX-2507.
Biacore analysis of hFcRn interaction with DX-2507 at pH 6.0
and pH 7.5 revealed that the kinetic constants for the interactions
of the variants were essentially identical to those determined for
DX-2504. The bioactivity of DX-2507 was further compared to
DX-2504 in pharmacologic and toxicokinetic studies in cynomol-
gus monkeys. Table 1 provides the kinetic constants for the inter-
action of hFcRn with DX-2504 and DX-2507, and the resulting
equilibrium dissociation constants (K d).
IgG CATABOLISM AND PHARMACOKINETICS OF DX-2504 IN TG32B
MICE (EXPERIMENT 1)
Since the phage screening was directed toward human-FcRn,
mouse experiments were conducted in human transgenic mice
(TG32B). Furthermore, since endogenous mouse IgG does
not recycle effectively through human-FcRn, human IgG was
Table 1 | Kinetic constants for interaction of DX-2504 and DX-2507
with FcRn.
DX-2504 DX-2507
pH kon
(M−1s−1)
koff
(s−1)
K d
(nM)
kon
(M−1s−1)
koff
(s−1)
K d
(nM)
6.0 2.4×105 3.5×10−4 1.5 1.3×105 2.4×10−4 1.8
7.5 1.5×105 2.8×10−4 1.9 1.0×105 2.4×10−4 2.0
administered to the transgenic mice to serve as a model for IgG
catabolism and FcRn antagonism. Therefore, transgenic mice were
pre-treated with an injection of hIgG, followed by SC administra-
tion of 5, 10, or 20 mg/kg DX-2504. A rapid and dose-dependent
acceleration of the catabolism of serum hIgG was observed as com-
pared to the control animals (Figure 1A). A similar reduction in
hIgG was observed following IV injection of DX-2504 (data not
shown).
The pharmacokinetics of DX-2504 (10 mg/kg) following IV
and SC administration was examined. As shown in Figure 1B,
DX-2504 levels dropped rapidly, becoming almost undetectable
after ~24 h following either SC or IV administration. In contrast,
hIgG possesses a prolonged pharmacokinetic profile as shown in
Figure 1A, with an approximate half-life of greater than 100 h.
IgG CATABOLISM AND PHARMACOKINETICS OF DX-2504 IN
CYNOMOLGUS MONKEYS (EXPERIMENT 2)
Based upon results in the TG32B mouse model, an initial
evaluation of pharmacology in non-human primates was per-
formed to investigate the effect of DX-2504 on the catabolism
of endogenous IgG.
Following IV or SC administration of DX-2504, a decrease
in total serum IgG concentration was observed at all doses
(Figure 2A). A dose-dependent response was observed, with
20 mg/kg, via either route, being more effective than 5 mg/kg. At
20 mg/kg, there was not a discernible difference in the efficacy of
DX-2504 given by either route of administration. The IV dose
of 5 mg/kg DX-2504 appears more effective than the same SC
dose. The maximum effect on IgG, i.e., ~60–68% depletion, was
achieved by day 10, although most of the decrease was observed by
day 7, after the first 20 mg/kg dose. Recovery of IgG levels began
3–4 days after the second dose. The serum concentrations of IgM,
IgA, and albumin remained approximately the same throughout
the 2 weeks of the experiment, although minor fluctuations were
noted (Figures 2B–D).
FIGURE 1 | IgG catabolism and pharmacokinetics of DX-2504 inTG32B
mice. (A) Dose response of IgG catabolism after 5, 10, or 20 mg/kg
DX-2504 administered subcutaneously to TG32B mice at 24 and 168 h.
(B) Pharmacokinetics of DX-2504 in TG32B mice after a single 10 mg/kg
intravenous (IV) or subcutaneous (SC) dose. Error bars represent standard
deviation.
Frontiers in Immunology | Immunotherapies and Vaccines April 2015 | Volume 6 | Article 176 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nixon et al. Fully human antibody inhibitors of FcRn
FIGURE 2 | IgG catabolism and pharmacokinetics of DX-2504
in cynomolgus monkeys. Dose-dependent reductions in (A) total
serum IgG but not (B) IgM, (C) IgA, or (D) albumin following
DX-2504 in cynomolgus monkeys. DX-2504 was administered
either intravenously (IV) or subcutaneously (SC) on days 0 and 7
(black arrows) at doses of 5 or 20 mg/kg. Data presented as
percentage of baseline (day 0). Error bars represent standard
deviation.
FIGURE 3 | Serum concentration of DX-2504 following intravenous or subcutaneous administration in cynomolgus monkeys. (A) Serum concentration
following 5 mg/kg DX-2504. (B) Serum concentration following 20 mg/kg DX-2504. DX-2504 was administered on days 0 and 7. Error bars represent standard
deviation.
DX-2504 concentrations were measured in serum from all
animals (Figure 3). Pharmacokinetic analysis was performed fol-
lowing each dose and results are presented in Table 2. Similar to the
results from transgenic mice, DX-2504 rapidly disappeared from
the circulation with a half-life less than 24 h following all doses
and routes of administration.
EFFECT OF DX-2504 ON PRIMARY AND SECONDARY IMMUNE
RESPONSES IN CYNOMOLGUS MONKEYS (EXPERIMENT 3)
Two model antigens, KLH and TT, known to elicit significant IgG
and IgM responses in cynomolgus monkeys were used to assess
the primary and secondary immune response in the presence of
DX-2504. The experiment was designed to examine the primary
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immune response to KLH and the secondary immune response to
TT. Table 3 provides an overview of the study design. DX-2504
was administered SC either on the same day as the two antigens
(second administration of TT and first administration of KLH) or
3 days following administration of the antigens.
DX-2504, administered at 20 mg/kg SC on a once weekly sched-
ule for 3 weeks (Groups 2 and 3), caused a decrease in total serum
IgG concentrations of approximately 60–65% after the second
dose (Figure 4A). DX-2504 had no effect on total serum con-
centrations of albumin (Figure 4B) or IgA (Figure 4C). There was
a noticeable increase in total serum IgM concentration by day 35,
1 week after the administration of KLH consistent with an immune
response to neo-antigens (Figure 4D). As expected, this increase
in IgM was not affected by DX-2504 given on the same day as the
antigens (Group 2, day 28) or 3 days after the antigens (Group 3,
day 31).
Administration of TT on day 0 caused a large increase in anti-
TT IgG antibodies in all animals by day 10 and a smaller increase
in anti-TT IgG antibodies in control animals (Group 1) after the
second injection of TT on day 28 (Figure 5A). Administration
of DX-2504 on the same day as TT (day 28, Group 2) or 3 days
after TT (day 31, Group 3) resulted in a reduction in anti-TT
Table 2 | DX-2504 pharmacokinetic parameters by dose following
intravenous (IV) and subcutaneous (SC) administration to
cynomolgus monkeys.
Dose (mg/kg) Route/day Cmax (µg/ml) AUC (µg/ml×h) t1/2 (h)
5 IV Day 0 114 1956 4.9
IV Day 7 120 1556 4.8
5 SC Day 0 2.7 95 13.3
SC Day 7 3.5 112 14.3
20 IV Day 0 596 13041 6.6
IV Day 7 475 11613 5.2
20 SC Day 0 121 6372 7.2
SC Day 7 132 5000 7.2
Table 3 | Study design to evaluate primary and secondary immune
response of cynomolgus monkeys following subcutaneous
administrations of 20mg/kg DX-2504.
Group Day
0
Day
28
Day
31
Day
35
Day
38
Day
42
Day
45
1 TT Vehicle Vehicle Vehicle
TT
KLH
2 TT DX-2504 DX-2504 DX-2504
TT
KLH
3 TT TT DX-2504 DX-2504 DX-2504
KLH
TT, tetanus toxoid; KLH, keyhole limpet hemocyanin.
IgG antibodies of ~50–60% (Figure 5A). Both schedules for DX-
2504 administration appeared to almost completely eliminate the
anti-TT IgG responses. There was also an increase in anti-TT
IgM antibodies after the first and second administrations of TT
(Figure 5B). Administration of DX-2504 caused no change in the
anti-TT IgM antibody responses, as expected (Figure 5B).
Immunization with KLH on day 28 caused a marked rise in
anti-KLH IgG antibodies within about 7 days and peak levels of
antibodies occurred by day 14 after immunization (Figure 6A).
Administration of DX-2504 inhibited the rise in anti-KLH IgG
antibodies, resulting in markedly lower antibody levels in Groups
2 and 3 compared to Group 1 (Figure 6A). Anti-KLH IgG anti-
body levels were the same on day 35, but by day 38, a difference in
the levels was observed. Anti-KLH IgM antibody levels also rose
sharply after immunization, but administration of DX-2504 had
no effect on these levels (Figure 6B).
PHARMACOLOGIC COMPARABILITY AND TOXICOKINETICS OF DX-2504
AND DX-2507 IN CYNOMOLGUS MONKEYS (EXPERIMENT 4)
In vitro and in vivo studies revealed DX-2504 to be a potent
and specific antagonist of human-FcRn. It effectively increased
the catabolism of exogenously administered IgG in mice and
reduced IgG levels in non-human primates with no apparent
effects on IgM, IgA, or albumin in non-human primates. However,
as noted, there was concern that an unpaired cysteine residue in
DX-2504 could impact antibody manufacturing and product sta-
bility, thereby disrupting future clinical development. To mitigate
this risk, DX-2507 was developed and the pharmacokinetics and
pharmacodynamics of the molecule compared to that of DX-2504.
Cynomolgus monkeys received two doses (once weekly,
20 mg/kg subcutaneous) of either DX-2504 or DX-2507. All ani-
mals survived to study termination. There were no clinical obser-
vations or effects on body weights noted for either treatment group
(data not shown). DX-2504 serum concentrations were detected
from 2 h post-dosing on study day 0 through study day 11 in two
animals and on study day 13 in a single animal (Figure 7). DX-
2507 serum concentrations were detected from 2 h post-dosing on
study day 0 through study days 11, 12, and 17 in individual animals
(Figure 7).
In general, the toxicokinetic parameters for each antibody were
consistent on study days 0 and 7; the exception being the greater
mean elimination t 1/2 value for DX-2504 on study day 0 (Table 4).
This is thought to be due to sustained serum concentration val-
ues ranging from 0.25 to 0.46µg/ml (observed on study days 5
through 7). The overall exposure of DX-2507 was greater than
that observed for DX-2504. The mean Cmax and AUClast values
for DX-2507 on either study day 0 or 7 were between two to three-
fold greater than the values calculated for DX-2504. The difference
in exposure is consistent with the greater reduction in IgG levels
in animals that were administered DX-2507.
Cynomolgus monkey IgG levels were reduced following the
administration of both DX-2504 and DX-2507 (Figure 8). Fol-
lowing administration on study day 0, mean total IgG levels were
reduced to 42 and 33% of pre-dosing baseline levels in the DX-
2504 and DX-2507 groups, respectively. Prior to administration on
study day 7, mean total IgG levels increased to 48 and 37% of pre-
dosing baseline levels in the same treatment groups. Following
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FIGURE 4 | Effect of DX-2504 in cynomolgus monkeys on primary
immune response to keyhole limpet hemocyanin (KLH) and secondary
immune response to tetanus toxoid (TT). Total serum (A) IgG, (B) albumin,
(C) IgA, and (D) IgM. Groups 1–3 received TT on day 0 and 28 (red arrows)
and KLH on day 28 (pink arrow). Group 1 received vehicle on days 28, 35, and
42 (black arrows). Group 2 received 20 mg/kg DX-2504 on days 28, 35, and 42
(black arrows). Group 3 received 20 mg/kg DX-2504 on days 31, 38, and 45
(blue arrows). Error bars represent standard deviation.
dose administration on study day 7, mean total IgG levels were
reduced to 42% of pre-dosing baseline values in the DX-2504
group and to 30% of pre-dosing baseline values in the DX-2507
group. Total IgG levels returned to pre-dosing baseline values on
study day 13 in the DX-2504-treated animals and on study day 21
in the DX-2507-treated animals.
DISCUSSION
Human IgG molecules are non-specifically taken up into the endo-
some where they bind to FcRn under acidic conditions and as such
are effectively rescued from the endosomal degradation pathway.
FcRn then recycles back to the cell surface where the antibodies are
released in the neutral pH conditions. We therefore reasoned that
an effective FcRn receptor antagonist would be one that not only
competed for IgG binding but would remain bound throughout
the cycle – both in the endosome at acidic pH and at the cell sur-
face at neutral pH. Since FcRn is also responsible for the extended
half-life of serum albumin, we also wanted an antibody that would
effectively block IgG binding without disturbing albumin binding.
Such a specific antibody is feasible since it has been demonstrated
that IgG and albumin bind opposite faces of the FcRn molecule
(32, 34, 56).
The context of FcRn as a membrane protein was an impor-
tant consideration in the design of our antibody selection strategy.
Since soluble domains, as compared to membrane bound forms,
may impact the function of antibodies that result from display
library selections, we opted to incorporate both the soluble form of
the FcRn/β2M heterodimer and the membrane-bound form into
the library selection strategy. ELISA-based screening approaches
were then used to identify selectants that met the above crite-
ria to move forward with additional characterization. Results of
in vivo testing in animal models and manufacturing considera-
tions then informed further optimization of candidates, leading
to the development of DX-2504 and subsequently DX-2507.
Studies carried out in transgenic mice expressing hFcRn
demonstrated that administration of DX-2504 led to increased
hIgG catabolism. However, studies of hFcRn antagonism in
rodents are of somewhat limited predictive value because of the
lack of human IgG synthesis to counterbalance IgG degradation,
as well as cross-species differences in FcRn reactivity (57). For this
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FIGURE 5 | Effect of DX-2504 on IgG and IgM immune response to
tetanus toxoid (TT). (A) Antigen-specific IgG upon TT re-challenge and
(B) IgM response. Groups 1–3 received TT on day 0 and 28 (red arrows) and
keyhole limpet hemocyanin (KLH) on day 28 (pink arrow). Group 1 received
vehicle on days 28, 35, and 42 (black arrows). Group 2 received 20 mg/kg
DX-2504 on days 28, 35, and 42 (black arrows). Group 3 received 20 mg/kg
DX-2504 on days 31, 38, and 45 (blue arrows). Error bars represent standard
deviation.
FIGURE 6 | Effect of DX-2504 on IgG and IgM immune response to
keyhole limpet hemocyanin (KLH). (A) IgG and (B) IgM to novel
antigen KLH. Groups 1–3 received tetanus toxoid on day 0 and 28 (red
arrows) and KLH on day 28 (pink arrow). Group 1 received vehicle on
days 28, 35, and 42 (black arrows). Group 2 received 20 mg/kg DX-2504
on days 28, 35, and 42 (black arrows). Group 3 received 20 mg/kg
DX-2504 on days 31, 38, and 45 (blue arrows). Error bars represent
standard deviation.
reason, we conducted additional studies in non-human primates.
In agreement with findings from the transgenic mouse studies, IV
or SC administration of DX-2504 to non-human primates was
effective at lowering serum concentrations of IgG by approxi-
mately 60%. DX-2504 had no effect on levels of total IgM, IgA,
or albumin. IgM and IgA do not bind FcRn and therefore one
would not expect an effect on levels of these two immunoglobulins.
However, albumin does bind to FcRn and the lack of an effect on
levels of albumin is a testament to the specificity of DX-2504 and
provides insight into the location of the antibody epitope.
There was a clear dose dependency to the depletion of IgG in
monkeys, with 20 mg/kg, either IV or SC, being more effective than
5 mg/kg by either route. At 20 mg/kg, there was no discernable dif-
ference between IV and SC dosing. This is important because it
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could allow for SC administration in the clinical setting. Similar
to the short half-life of DX-2504 observed in transgenic mice, DX-
2504 rapidly disappeared from the circulation of non-human pri-
mates. It is conceivable that the FcRn receptor occupancy of DX-
2504 prevents accurate clearance estimates from serum drug levels.
Results from the examination of DX-2504 on the primary and
secondary immune response in non-human primates were in line
with expectations for treatment with an anti-FcRn antibody. Total
IgG levels decreased rapidly after administration, while concentra-
tions of albumin, IgM, and IgA were unchanged. Anti-KLH and
anti-TT IgG antibodies were lowered to approximately the same
level as total IgG levels (50–70% reduction) when compared to
control animals.
The immune response to KLH was robust, as expected, and
only the anti-KLH IgG antibodies were affected by treatment
with DX-2504; anti-KLH IgM antibodies were unchanged. It
is also of note that the anti-KLH IgG response was initially
robust, but eventually markedly reduced by DX-2504 treatment.
Taken together, the results suggest that DX-2504 has a specific
effect on IgG type immunoglobulins but does not interfere with
other classes of immunoglobulins and the humoral antibody
response to novel antigens. Thus, FcRn antagonism represents a
promising treatment strategy for autoantibody-mediated autoim-
mune diseases by targeting the IgG autoantibody, the end point
FIGURE 7 | Serum concentrations following subcutaneous (SC)
administration of DX-2504 and DX-2507 to cynomolgus monkeys.
Animals received 20 mg/kg DX-2504 or DX-2507 on days 0 and 7. Error bars
represent standard deviation.
of the pathogenic humoral immune reaction without significantly
suppressing normal immune function.
While DX-2504 possessed several of the characteristics impor-
tant to the development of a therapeutic antibody targeting FcRn,
there was concern over its manufacturability due to an unpaired
cysteine in LC-CDR3. The ability to produce and maintain the
tertiary and quaternary structure of a human therapeutic anti-
body through manufacturing to storage is a key consideration in
translating novel discoveries into therapeutic strategies in clinic.
To mitigate the risk of the unpaired cysteine disrupting the
advancement of the molecule in clinical development, variants
of DX-2504 were created. DX-2507, a variant in which the free
cysteine was changed to an alanine, bound to FcRn with similar
affinity to that of DX-2504. It was well-tolerated and possessed
a slightly improved pharmacokinetic profile with overall expo-
sure two to threefold greater than that observed for DX-2504 in
non-human primates. DX-2507 reduced total IgG levels by>60%
following two subcutaneous injections and levels returned to pre-
dose baseline values approximately a week following the second
injection.
Interestingly, the terminal half-life of both DX-2504 and DX-
2507 following either IV or SC administration to non-human pri-
mates was on the order of hours but resulted in prolonged reduc-
tions in serum IgG (~1 week). The high affinity of the antibodies
FIGURE 8 |Total IgG as a percentage of baseline (day 0) in cynomolgus
monkeys following subcutaneous (SC) administration of DX-2504 or
DX-2507. Animals received 20 mg/kg DX-2504 or DX-2507 on days 0 and 7.
Error bars represent standard deviation.
Table 4 | Mean (SD) toxicokinetic parameters following SC administration to cynomolgus monkeys.
Test article Study day Cmax (µg/ml) Tmax (day) AUC (µg/ml×day) CL/F (ml/day/kg) Vz/F (ml/kg) t1/2 (day)
DX-2504 Day 0 51.9 (25.8) 0.8 70.8 (32.2) 341.0 (204.5) 879.1 (407.0) 1.9 (0.2)
Day 7 32.0 (15.7) 7.8 47.5 (20.0) 492.3 (264.0) 312.4 (252.0) 0.4 (0.1)
DX-2507 Day 0 75.3 (19.7) 1.0 135.6 (29.4) 152.0 (31.8) 74.1 (35.0) 0.3 (0.1)
Day 7 71.6 (4.7) 8.0 120.3 (3.2) 166.3 (4.3) 73.6 (24.8) 0.3 (0.1)
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for FcRn at neutral pH may provide a possible explanation for this
apparent lack of a correlation between pharmacokinetic and phar-
macodynamic activities. Endogenous IgG has limited affinity for
FcRn at physiological pH and therefore dissociates when recycled
back to the cell surface following binding to FcRn in the endo-
some. Estimates for the binding of endogenous IgG via Fc domains
range from low nanomoles at pH 6 and negligible to >1µM at
pH 7.4 (58, 59). In contrast, the high affinity of the engineered
antibodies supports the concept that they remain largely bound
to the receptor upon exocytosis to the cell surface. Indeed, Biacore
studies demonstrated that DX-2504 and DX-2507 bind to hFcRn
with high affinity at both pH 6.0 (K d= 1.5 and 1.8 nM, respec-
tively) and pH 7.4 (K d= 1.9 and 2.0 nM, respectively). Thus, the
high affinity at pH 7.4 may prevent it from following the natural
recycling pathway which typically provides IgG their long serum
half-lives in vivo. Alternatively, we cannot rule out the possibility
of irreversible binding of the FcRn-inhibitors to FcRn in vivo. To
date, we have not generated experimental data in support of either
possibility.
Recognition of the importance of FcRn in mediating IgG home-
ostasis represents a promising therapeutic strategy for the treat-
ment of antibody-mediated autoimmune diseases. FcRn antag-
onism may also be a compelling strategy for the management of
neutralizing anti-drug antibodies associated with biologic replace-
ment therapies, such as those observed with replacement proteins
for hemophilia and lysosomal storage diseases. The antibodies
described are capable of reducing total and antigen-specific IgG
>60% in vivo, which is in line with data suggesting that clinical
improvements can be achieved in several autoimmune diseases
when autoantibody levels are reduced >50% (60–62). Impor-
tantly, FcRn antagonism does not totally abolish serum IgG which
reduces the risk of hypogammaglobulinemia. The lack of an effect
on other classes of antibodies, as well as the primary response to
novel antigen, also suggests FcRn antagonism may result in less
immune system disruption and less infection risk. Ultimately, the
safety of an anti-FcRn therapeutic approach can only be born out
in human clinical trials but these data provide important proof of
concept and support the viability of the approach.
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